All studies evaluating PSMA radioligand PET/CT in ccRCC reported a good performance in assessing the presence of pathological findings in different anatomic sites, including the bone, brain, lymph nodes and soft tissues [48,49,50,51,53,54,55,56,57,58,59,60,61,62,63]. This evidence concerns the gene FOLH1 and nonpapillary renal cell carcinoma.